EANS-News: AGENNIX AG / Agennix AG to Present at Two Investor Conferences in February

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Presentation; Investor Conferences

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, January 26, 2011 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that the Company will be presenting at two
investor conferences in February.

The Company will give a corporate presentation at the upcoming Close
Brothers Seydler Bank AG Small and Mid Cap Conference. The
presentation will be on Wednesday, February 2, 2011, at 15:40 CET at
the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.

Agennix will also give a presentation at the 13th Annual BIO CEO &
Investor Conference in New York, NY, USA. The presentation is
scheduled for Tuesday, February 15, 2011 at 9:00 AM ET/15:00 CET at
The Waldorf Astoria Hotel. A live audio webcast will be available
through the Agennix Web site at www.agennix.com. A replay will be
available on the Web site following the live event.

Additionally, as part of the conference, Dr. Rajesh Malik, Chief
Medical Officer of Agennix AG, will participate on a panel entitled,
"Oncology: Lung Cancer - Clearing the Airways on New Treatments." The
panel is scheduled for Monday, February 14, 2011 at 9:00 AM ET.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix's registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

AgennixTM is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Barbara Müller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade